Adamis Pharmaceuticals Schedules First Quarter 2020 Earnings Conference Call and Business Update
May 15 2020 - 9:00AM
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
(“Adamis”) announced today that it will host an investor conference
call on Monday, May 18, 2020 at 2:00 pm Pacific
Time to discuss its financial and operating results for the
first quarter of 2020 as well as provide an update on business
developments and activities. The company’s press release concerning
its first quarter 2020 financial results will be available
after 1:00 p.m. Pacific Time on May 18, 2020, on its
website at www.adamispharmaceuticals.com, and the company also
expects to file its quarterly report on Form 10-Q for the first
quarter ended March 31, 2020, on that date.
Event: Adamis Pharmaceuticals First
Quarter 2020 Conference CallDate: Monday, May
18, 2020Time: 2:00 pm PT (5:00 pm
ET)US Dial-in (Toll
Free): 1-877-423-9813TOLL/International
Dial-in: 1-201-689-8573Conference
ID: 13703885
Dr. Dennis J. Carlo, President and CEO of Adamis, will host
the call along with other members of the management team. The call
is open to the public and will provide an update on recent
developments, events that have taken place during this quarter and
certain target milestones and goals for future periods.
Forward-looking statements concerning expectations regarding future
company performance may be made during the conference call.
A live audio webcast of the conference call will also be
available via this link –
http://public.viavid.com/index.php?id=139872.
Participants should access this webcast site 10 minutes before the
start of the call. In addition, a telephone playback of the call
will be available after approximately 5:00 pm
PT on May 18, 2020. To listen to the replay, call toll
free 1-844-512-2921 within the United States or
1-412-317-6671 when calling internationally (toll). Please use the
replay PIN number 13703885.
About Adamis
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company primarily focused on developing and
commercializing products in various therapeutic areas, including
respiratory disease, allergy and opioid overdose. The company’s
SYMJEPI (epinephrine) Injection 0.3mg and SYMJEPI (epinephrine)
Injection 0.15mg products were approved by the FDA for use in the
emergency treatment of acute allergic reactions, including
anaphylaxis. In July 2019, Sandoz, a division of Novartis Group,
announced it had fully launched both in the U.S. Please refer to
www.SYMJEPI.com for additional product information. Adamis is
developing additional products, including a naloxone injection
product candidate, ZIMHI, for the treatment of opioid overdose, and
a metered dose inhaler and dry powder inhaler product candidates
for the treatment of asthma and COPD. The company’s subsidiary,
U.S. Compounding, Inc., compounds sterile prescription drugs, and
certain nonsterile drugs for use by hospitals, clinics and surgery
centers throughout most of the United States.
Contact Mark Flather Senior Director, Investor
Relations & Corporate Communications Adamis Pharmaceuticals
Corporation (858) 412-7951 mflather@adamispharma.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Sep 2023 to Sep 2024